Comparable stake leader
FORWARD VENTURES V LP
SEC ownership of Viracta Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001061027.
Disclosed value leader
Ivor Royston
Comparable rows
1/17
Latest evidence
31 Dec 2024
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FORWARD VENTURES V LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 17
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FORWARD VENTURES V LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001061027
- Issuer location
- Cardiff, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Viracta Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FORWARD VENTURES V LP
Disclosed value leader
Ivor Royston
Comparable rows
1/17
Latest evidence
31 Dec 2024
13D/G
3/4/5
Lead comparable stake: 4.3%
16 rows are not safely comparable across share classes.
13D/G row: FORWARD VENTURES V LP
Showing 1-8 of 17 holder rows.
Quick read
FORWARD VENTURES V LP leads the comparable SEC ownership view at 4.3%.
1 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FORWARD VENTURES V LP's linked filing trail.
Comparable ownership
Top 1
FORWARD VENTURES V LP
4.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FORWARD VENTURES V LP |
13D/G
|
4.3%
|
$16,952
847,600 shares
|
$0 | 31 Dec 2024 |
| Ivor Royston |
3/4/5
Director
|
—
mixed-class rows
|
$665,407
958,778 shares
mixed-class rows
|
— | 25 Nov 2024 |
| Roger Pomerantz |
3/4/5
Director
|
—
mixed-class rows
|
$105,837
163,297 shares
mixed-class rows
|
— | 25 Nov 2024 |
| Daniel R. Chevallard |
3/4/5
CFO and COO
|
—
mixed-class rows
|
$91,896
336,750 shares
mixed-class rows
|
— | 12 Mar 2024 |
| Lisa Rojkjaer |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$77,579
235,233 shares
mixed-class rows
|
— | 16 Mar 2023 |
| Mark Rothera |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$49,320
575,000 shares
mixed-class rows
|
— | 12 Mar 2024 |
| Michael E. Faerm |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
500,000 shares
|
— | 14 May 2024 |
| Darrel P. Cohen |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
120,000 shares
|
— | 12 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Viracta Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Ivor Royston
Net 12M change
$0
Latest report
25 Nov 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ivor Royston | Director | $665,407 | Mixed | 25 Nov 2024 | ||
| Roger Pomerantz | Director | $105,837 | Mixed | 25 Nov 2024 | ||
| Daniel R. Chevallard | CFO and COO | $91,896 | Mixed | 12 Mar 2024 | ||
| Lisa Rojkjaer | Chief Medical Officer | $77,579 | Mixed | 16 Mar 2023 | ||
| Mark Rothera | President and CEO, Director | $49,320 | Filing P/S | 12 Mar 2024 | ||
| Flavia Borellini | Director | Mixed | 20 Jun 2024 | |||
| Darrel P. Cohen | Chief Medical Officer | Mixed | 12 Mar 2024 | |||
| Thomas E. Darcy | Director | Mixed | 20 Jun 2024 | |||
| Samuel Lafayette Murphy | Director | Mixed | 20 Jun 2024 | |||
| Michael Huang | Director | Mixed | 09 Jun 2022 | |||
| Nicole Onetto | Director | Mixed | 09 Jun 2022 | |||
| Barry J. Simon | Director | Mixed | 20 Jun 2024 | |||
| Stephen Rubino | Director | Mixed | 20 Jun 2024 | |||
| Michael E. Faerm | Chief Financial Officer | Mixed | 14 May 2024 | |||
| Melody Burcar | Senior VP, Finance | Mixed | 20 Mar 2024 | |||
| Jane F. Barlow | Director | Mixed | 20 Jun 2024 | |||
| Jane Chung | Director | Mixed | 20 Jun 2024 |
Recent insider transactions for Viracta Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.